42 CFR 441.25
§ 441.25 Prohibition on FFP for certain prescribed drugs.
United States · 42 CFR — Public Health · Status: effective
Cite this
- Citation
- 42 CFR 441.25, § 441.25 Prohibition on FFP for certain prescribed drugs, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/206277
- Permanent ID
ys:prov:206277@1- SHA-256
6ab21669df8c99648c840bfa92ae9e1a70a093631687ed0228a6518825146894
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) FFP is not available in expenditures for the purchase or administration of any drug product that meets all of the following conditions:
(1) The drug product was approved by the Food and Drug Administration (FDA) before October 10, 1962.
(2) The drug product is available only through prescription.
(3) The drug product is the subject of a notice of opportunity for hearing issued under section 505(e) of the Federal Food, Drug, and Cosmetic Act and published in the Federal Register on a proposed order of FDA to withdraw its approval for the drug product because it has determined that the product is less than effective for all its labeled indications.
(4) The drug product is presently not subject to a determination by FDA, made under its efficacy review program (see 21 CFR 310.6 for an explanation of this program), that there is a compelling justification of the drug product's medical need.
(b) FFP is not available in expenditures for the purchase or administration of any drug product that is identical, related, or similar, as defined in 21 CFR 310.6, to a drug product that meets the conditions of paragraph (a) of this section.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.